Comparative Pharmacology
Head-to-head clinical analysis: DUAVEE versus EVISTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUAVEE versus EVISTA.
DUAVEE vs EVISTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUAVEE is a combination of conjugated estrogens (CE) and bazedoxifene (BZA). CE activates estrogen receptors (ERα and ERβ) to relieve menopausal symptoms; BZA is a selective estrogen receptor modulator (SERM) that antagonizes ER in the endometrium to prevent endometrial hyperplasia.
Selective estrogen receptor modulator (SERM) that binds to estrogen receptors, acting as an agonist in bone and antagonist in breast and uterine tissues.
One tablet (conjugated estrogens 0.45 mg/bazedoxifene 20 mg) orally once daily.
60 mg orally once daily.
None Documented
None Documented
Conjugated estrogens: terminal half-life of estrone sulfate is approximately 10-24 hours. Bazedoxifene: terminal half-life is approximately 30 hours. Clinically, steady state is achieved within 7 days for estrogens and 10-14 days for bazedoxifene.
Terminal elimination half-life is approximately 32.5 hours (range 27-39 hours) for raloxifene and its glucuronide conjugates; clinically relevant for once-daily dosing.
Conjugated estrogens are primarily excreted in urine as glucuronide and sulfate conjugates, with approximately 10-15% excreted in feces via biliary elimination. Bazedoxifene is mainly eliminated in feces (85%) with minimal renal excretion (<1% as unchanged drug).
Raloxifene undergoes extensive glucuronidation; <0.1% excreted unchanged in urine. Approximately 95% is excreted in feces over 5 days (primarily as glucuronide conjugates). Renal elimination of unchanged drug is negligible (<0.1%).
Category C
Category C
Selective Estrogen Receptor Modulator/Estrogen Combination
Selective Estrogen Receptor Modulator